OS Therapies Incorporated OSTX 深 沪
已收盘 02-06 16:00:00 美东时间
1.36
+0.090
+7.09%
华盛通- 最 高1.435
- 今 开1.30
- 成交量 63.11万股
- 最 低 1.295
- 昨 收 1.27
- 总市值 4789.15万
- 52周最高 2.57
- 市盈率 静 --
- 换手率 1.79%
- 52周最低 1.12
- 委 比 0.00%
- 总股本 3521.44万
- 历史最高 7.00
- 量 比 1.18
- 振 幅 11.02%
- 历史最低 1.12
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OS Therapies Begins FDA Filing for Experimental Cancer Treatment Aimed at Osteosarcoma Recurrence
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that it has formally initiated a Biologics License Application (BLA) submission
02-02 19:02
OS Therapies Announces Biomarker Data From Phase 2b Clinical Trial Of OST-HER2 In Prevention Or Delay Of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)Pre-specified pathway analysis strategy developed as a result of
01-15 20:07
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
OS Therapies Targets FDA Approval for Bone Cancer Drug, Plans Animal Health IPO and $160M Voucher
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today provided stakeholders with a corporate outlook for the first half 2026.The outlook
01-05 20:43
OS Therapies Held An FDA Type C Meeting Regarding The Phase 2B Trial Of OST-HER2 To Prevent Or Delay Recurrent, Fully-resected, Pulmonary Metastatic Osteosarcoma, And Intends To File BLA By The End January 2026
FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated Approval Program
2025-12-15 19:13
OS Therapies Says U.S. FDA Grants Waiver Of Application Fee For BLA Filing Of OST-HER2; Type C Meeting With FDA Scheduled On December 11
U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency on December 8,
2025-12-05 21:09
OS Therapies Announces WHO's INN Expert Committee Approves Daznelimgene Lisbac For Non-Proprietary Name For Company's HER2
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that the International Nonproprietary Names (INN) Expert Committee of the World
2025-11-25 22:27
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.
2025-11-17 21:17
